Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.

TitrePrimary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
Publication TypeJournal Article
Year of Publication2017
AuthorsFraga, M, Fournier, N, Safroneeva, E, Pittet, V, Godat, S, Straumann, A, Nydegger, A, Vavricka, SR, Moradpour, D, Schoepfer, AM
Corporate AuthorsGroup, SIBDCohort
JournalEuropean journal of gastroenterology & hepatology
Date Published01/2017
Mots-clésAdolescent, Adult, Age of Onset, Appendectomy/adverse effects, Chi-Square Distribution, Child, Cholangitis, Colitis, Crohn Disease/diagnosis, Crohn Disease/epidemiology, Crohn Disease/mortality, Crohn Disease/therapy, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Prevalence, Risk Factors, Sclerosing/diagnosis, Sclerosing/epidemiology, Sclerosing/mortality, Sclerosing/therapy, Sex Factors, Smoking/epidemiology, Switzerland/epidemiology, Time Factors, Ulcerative/diagnosis, Ulcerative/epidemiology, Ulcerative/mortality, Ulcerative/therapy, Young Adult

BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD). We aimed to assess the prevalence of PSC in the Swiss Inflammatory Bowel Disease Cohort Study, to identify associated risk factors, and to describe the long-term evolution.

PATIENTS AND METHODS: Data of patients enrolled into the Swiss Inflammatory Bowel Disease Cohort Study were analyzed. Logistic regression modeling was performed to identify risk factors for PSC.

RESULTS: Among 2744 patients [1188 ulcerative colitis (UC); 1556 Crohn's disease (CD)], 57 had PSC (48 UC-PSC, nine CD-PSC). The prevalence of PSC was higher in UC compared with CD (4.04 vs. 0.58%, P<0.001). We identified the following significant independent risk factors for PSC in patients with UC: male sex [odds ratio (OR) 2.771, P=0.022], pancolitis (OR 2.855, P=0.011), nonsmoker at diagnosis (OR 9.253, P=0.030), and a history of appendicectomy (OR 4.114, P=0.019). During a median follow-up time of 74.8 months, four (7.0%) of PSC patients developed cholangiocarcinoma, six (10.5%) underwent liver transplantation, and five (8.8%) died. Survival of IBD-PSC patients was significantly worse compared with IBD patients without PSC (P=0.001). UC-PSC patients developed significantly more frequently colorectal cancer compared with UC patients without PSC (2/48 vs. 9/1440, P=0.017).

CONCLUSION: Approximately 4% of UC patients and 0.6% of CD patients had PSC. Male sex, pancolitis, nonsmoker status, and a history of appendicectomy were significantly associated with PSC. PSC is associated with considerable morbidity and mortality in the long term.

Alternate URL



Alternate JournalEur J Gastroenterol Hepatol
Citation Key / SERVAL ID7860
Peer reviewRefereed
PubMed ID27622999


Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 |

Go to top